It provides opportunities for therapeutic interventions, such as developing PI3K inhibitors to target PIK3CA-mutant cancers; mTOR inhibitors to act as downstream blockade and counteract PTEN-loss-driven activation; and using combination therapies to target RTKs, PI3K, and AKT synergistically and overcome resistance mechanisms [45]. This evidence concerns the gene PTEN and cancer.